Pregled bibliografske jedinice broj: 1238561
Pharmacogenomics of rosuvastatin – impact of ABCG2 and SLCO1B1 polymorphisms and drug-drug interactions on development of adverse drug reactions
Pharmacogenomics of rosuvastatin – impact of ABCG2 and SLCO1B1 polymorphisms and drug-drug interactions on development of adverse drug reactions // Pharmaca, 52 (2022), Suppl 2
Zagreb, 2022. str. 139-139 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1238561 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pharmacogenomics of rosuvastatin – impact of ABCG2 and SLCO1B1 polymorphisms and drug-drug interactions on development of adverse drug reactions
Autori
Ganoci, Lana ; Mucalo, Iva ; Bićanić, Lucija Ana ; Palić, Jozefina ; Šimičević, Livija ; Vrkić Kirhmajer, Majda ; Samardžić, Jure ; Božina, Tamara
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Pharmaca, 52 (2022), Suppl 2
/ - Zagreb, 2022, 139-139
Skup
10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation
Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
ABCG2 ; SLBO1B1 ; polymorphisms ; rosuvastatin
Sažetak
Introduction: ABCG2 c.421C>A and SLCO1B1 c.521T>C polymorphisms are associated with a reduced transporter function and higher exposure to rosuvastatin. We investigated the relationship between ABCG2 and SLCO1B1 polymorphisms, drugdrug interactions (DDIs) and rosuvastatin-related myotoxicity and hepatotoxicity. Patients and methods: In this case-control study, cases were subjects that developed rosuvastatinrelated myotoxicity and hepatotoxicity and control subjects were rosuvastatin-treated patients free of adverse drug reactions (ADRs). Patients were enrolled retrospectively and prospectively for 3, 5 years, and their clinical data, concomitant therapy and rosuvastatin-related myotoxicity and hepatotoxicity occurrence were evaluated. All subjects were genotyped for ABCG2 c.421C>A and SLCO1B1 c.521T>C by TaqMan® real-time PCR method. Using the individuals' medication lists and Lexicomp® clinical decision support system, the prevalence of DDI and drug-drug- gene interactions (DDGIs) were analysed. Results: A total of 356 subjects were recruited (cases (n=128), controls (n=228)). SLCO1B1 c.521T>C variant carriers had 1, 4- times greater odds (95% CI: 0, 92-2, 20 ; χ² = 6, 333 ; p=0, 042), and ABCG2 c.421C>A variant carriers had 1, 9-times greater odds (95% CI: 1, 18- 3, 33 ; χ² = 6, 814 ; p=0, 009) of developing rosuvastatin ADRs. The number of clinically relevant DDI that could have contributed to ADRs was low, both in a group of cases (n=16) and in a control group (n=50). There was no statistically significant difference in the rate of DDGIs between both groups. Conclusions: In our study, preliminary data showed an association between ABCG2 c.421C>A and SLCO1B1 c.521T>C polymorphisms and rosuvastatin- related myotoxicity and hepatotoxicity. At the same time, there was no association between rosuvastatin DDIs, ABCG2 and SLCO1B1 polymorphisms and rosuvastatin- related ADR
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
HRZZ-UIP-2020-02-8189 - Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova (PGx-CardioDrug) (Božina, Tamara, HRZZ - 2020-02) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Iva Mucalo
(autor)
Lana Ganoci
(autor)
Jure Samardžić
(autor)
Tamara Božina
(autor)
Majda Vrkić Kirhmajer
(autor)
Lucija Ana Bićanić
(autor)
Jozefina Palić
(autor)
LIVIJA ŠIMIČEVIĆ
(autor)